RevMed's RAS inhibitor gains landmark FDA approval for pancreatic cancer.
Nature Reviews Drug Discovery · · News
RevMed's RAS inhibitor gains landmark FDA approval for pancreatic cancer.
- In the news
The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.
Read the brief in JClub →Why it is on JClub this week
Covered by 1 news source.
- News stories
- 1
- news
- carry
Signals for the week to 3 Oct 2026 · everything that moved →
Related in JClub
Nature Medicine · · Clinical Trial, Phase II
Over 59% of pancreatic cancer patients treated with daraxonrasib develop resistance through RAS pathway alterations, including KRAS amplification and RTK upregulation.
- Open access
- 5 cites
EMBO Journal · · Journal Article
CDK8 drives immune evasion and resistance in PDAC by remodeling the tumor microenvironment during KRAS G12D inhibition, with 50% of cases showing resistance.
- Open access
- 3 cites
New England Journal of Medicine · · Randomized Controlled Trial
Daraxonrasib significantly improves overall survival and progression-free survival in previously treated metastatic pancreatic ductal adenocarcinoma, with median overall survival of 13.2 months versus 6.6 months for chemotherapy.
- 97 cites